ArticleFrontiers in drug safety and regulation2025
Reporting rates of abnormal uterine bleeding after COVID-19 vaccination in South Korea.
Article in Frontiers in drug safety and regulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Abnormal uterine bleeding after COVID-19 vaccination has been reported, but few studies have characterized population-level reporting rates. We evaluated AUB reporting in South Korea. Methods: We analyzed suspected adverse reactions reported to the Korea Disease Control and Prevention Agency from 26 February 2021 to 29 June 2023 (week 121). Cases with AUB were identified, and reporting rates were compared across vaccine types and doses. Results: During the study period, 135,894,788 doses were administered, with 483,391 suspected adverse reactions (356 per 100,000) and 6,288 AUB reports (4.9 per 100,000). AUB ranked 15th among reported adverse events. Reporting rates varied by manufacturer and dose. Discussion: These descriptive pharmacovigilance findings do not estimate incidence or imply causality. Prospective, controlled studies are needed to clarify causal relationships and to inform diagnostic and management protocols for AUB after vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.